KR101820987B1 - 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체 - Google Patents

클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체 Download PDF

Info

Publication number
KR101820987B1
KR101820987B1 KR1020127029208A KR20127029208A KR101820987B1 KR 101820987 B1 KR101820987 B1 KR 101820987B1 KR 1020127029208 A KR1020127029208 A KR 1020127029208A KR 20127029208 A KR20127029208 A KR 20127029208A KR 101820987 B1 KR101820987 B1 KR 101820987B1
Authority
KR
South Korea
Prior art keywords
toxin
delete delete
antibody
clostridium difficile
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127029208A
Other languages
English (en)
Korean (ko)
Other versions
KR20130062279A (ko
Inventor
당쉬 마
커스텐 나가시마
브라이언 케네디
제랄드 피. 도노반
윤 강
윌리암 씨. 올손
생카르 쿠마르
나오야 추루시타
안드레 제이. 마로즈산
알버트 쿠포
Original Assignee
프로제닉스 파머슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로제닉스 파머슈티컬스, 인코포레이티드 filed Critical 프로제닉스 파머슈티컬스, 인코포레이티드
Publication of KR20130062279A publication Critical patent/KR20130062279A/ko
Application granted granted Critical
Publication of KR101820987B1 publication Critical patent/KR101820987B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020127029208A 2010-04-15 2011-04-15 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체 Active KR101820987B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32450310P 2010-04-15 2010-04-15
US61/324,503 2010-04-15
US38166910P 2010-09-10 2010-09-10
US61/381,669 2010-09-10
PCT/US2011/032713 WO2011130650A2 (en) 2010-04-15 2011-04-15 Antibodies for the treatment of clostridium difficile-associated infection and disease

Publications (2)

Publication Number Publication Date
KR20130062279A KR20130062279A (ko) 2013-06-12
KR101820987B1 true KR101820987B1 (ko) 2018-01-22

Family

ID=44799348

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127029208A Active KR101820987B1 (ko) 2010-04-15 2011-04-15 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체

Country Status (11)

Country Link
US (2) US8986697B2 (enExample)
EP (1) EP2558493B1 (enExample)
JP (2) JP5965389B2 (enExample)
KR (1) KR101820987B1 (enExample)
CN (1) CN102947334B (enExample)
AU (1) AU2011239470B2 (enExample)
BR (1) BR112012026021B1 (enExample)
CA (1) CA2795953C (enExample)
ES (1) ES2757675T3 (enExample)
MX (1) MX339253B (enExample)
WO (1) WO2011130650A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5965389B2 (ja) 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
EP3167899B1 (en) 2010-09-03 2021-03-24 Valneva Austria GmbH Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof
CA2845884A1 (en) 2011-08-22 2013-02-28 Cangene Corporation Clostridium difficile antibodies
WO2013038156A1 (en) * 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
SG11201402375VA (en) * 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
CN102590515B (zh) * 2012-01-13 2014-07-30 张春华 艰难梭菌外毒素a检测试剂盒及组成该试剂盒的单克隆抗体
AU2013212264B2 (en) * 2012-01-23 2017-05-18 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to clostridium infections
RU2628305C2 (ru) 2012-03-02 2017-08-15 Регенерон Фармасьютиказ, Инк. Человеческие антитела к токсинам clostridium difficile
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
EP2921502A4 (en) 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
JP2016501877A (ja) * 2012-11-28 2016-01-21 シーエヌジェー ホールディングス，インコーポレイテッド クロストリジウム・ディフィシルに対する抗体
CN107880126B (zh) 2012-12-21 2021-03-30 西雅图基因公司 抗ntb-a抗体及相关组合物和方法
EP4079760A3 (en) 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
CN105555309A (zh) * 2013-04-19 2016-05-04 英穆伦有限公司 治疗和/或预防艰难梭菌相关疾病的方法和组合物
CA2910200A1 (en) 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
WO2016156475A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
JP2018517670A (ja) * 2015-04-15 2018-07-05 メディミューン，エルエルシー クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）感染および関連疾患の治療方法
GB201509326D0 (en) * 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
SG11201808246SA (en) * 2016-03-24 2018-10-30 Paratek Pharm Innc Methods for treating and preventing c. difficile infection
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018148537A1 (en) * 2017-02-10 2018-08-16 Stc. Unm Recombinant expression systems and products
JP7339262B2 (ja) * 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
GB201807367D0 (en) * 2018-05-04 2018-06-20 Univ Newcastle Biomarker
RU2694549C1 (ru) * 2018-08-16 2019-07-16 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр здоровья детей" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ здоровья детей" Минздрава России) Способ ведения детей с болезнью Гиршпрунга в периоперационном периоде
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121422A2 (en) 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292668A (en) 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US6071517A (en) 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1833510A4 (en) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP2033657A1 (de) 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
JP5965389B2 (ja) 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121422A2 (en) 2004-02-06 2006-11-16 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Infection and Immunity. 2006, 74, 6339-6347.*

Also Published As

Publication number Publication date
CN102947334A (zh) 2013-02-27
EP2558493A4 (en) 2013-11-27
MX2012011926A (es) 2013-01-29
KR20130062279A (ko) 2013-06-12
EP2558493A2 (en) 2013-02-20
CA2795953A1 (en) 2011-10-20
US20130202618A1 (en) 2013-08-08
ES2757675T3 (es) 2020-04-29
MX339253B (es) 2016-05-18
US20150175681A1 (en) 2015-06-25
AU2011239470A1 (en) 2012-11-01
JP2013523190A (ja) 2013-06-17
WO2011130650A2 (en) 2011-10-20
EP2558493B1 (en) 2019-09-18
CA2795953C (en) 2021-09-14
BR112012026021B1 (pt) 2022-05-03
JP2017012166A (ja) 2017-01-19
AU2011239470B2 (en) 2015-09-10
CN102947334B (zh) 2017-12-26
US8986697B2 (en) 2015-03-24
WO2011130650A3 (en) 2012-04-12
BR112012026021A2 (pt) 2020-04-14
JP6159854B2 (ja) 2017-07-05
JP5965389B2 (ja) 2016-08-03

Similar Documents

Publication Publication Date Title
KR101820987B1 (ko) 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
US12240918B2 (en) Bispecific antibodies against plasma kallikrein and factor XII
CN107001472B (zh) 对cd73具有特异性的结合分子及其用途
KR101732056B1 (ko) 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
CA2781050C (en) Pcsk9 antagonists
CN101687031B (zh) 用于治疗眼疾和眼病的组合物及方法
WO2015164865A1 (en) Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
KR20150139909A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
KR20130066682A (ko) 항체 표적 파골세포－관련 단백질 ｓｉｇｌｅｃ－１５
US20240301056A1 (en) Anti-l1cam antibodies and uses thereof
KR20230060531A (ko) Pd-1에 결합하는 항체 및 이의 용도
RU2834713C1 (ru) Антитела, связывающие il4r, и их применение
KR102705172B1 (ko) 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
RU2630663C2 (ru) Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
HK40125826A (zh) 抗l1cam抗体及其用途
HK1179982B (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
HK1179982A (en) Antibodies for the treatment of clostridium difficile-associated infection and disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160414

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170629

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20171204

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180116

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180116

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20201216

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20211215

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20231218

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20241224

Start annual number: 8

End annual number: 8